Here's Why You Should Retain Carpenter Technology Stock for Now
CRS rides strong Aerospace and Defense demand, robust bookings and backlog, with management eyeing $660-$700M fiscal 2026 operating income.
3 Reasons Why Growth Investors Shouldn't Overlook Carpenter (CRS)
Carpenter (CRS) could produce exceptional returns because of its solid growth attributes.
Are You Looking for a Top Momentum Pick? Why Carpenter Technology (CRS) is a Great Choice
Does Carpenter Technology (CRS) have what it takes to be a top stock pick for momentum investors? Let's find out.
Is Carpenter Technology (CRS) Stock Outpacing Its Basic Materials Peers This Year?
Here is how Carpenter Technology (CRS) and Rio Tinto (RIO) have performed compared to their sector so far this year.
Cavendish sees Poolbeg's POLB 001 gaining strategic importance as CRS research expands
Cavendish has taken an upbeat view of Poolbeg Pharma PLC's (AIM:POLB, OTC:POLBF) prospects after the company's anti-inflammatory candidate POLB 001 was selected as a central element of a major UK research programme into cytokine release syndrome. CRS is a dangerous immune reaction that can occur during advanced cancer treatments such as bispecific antibodies and CAR-T therapies.
Carpenter Technology: Why FY27 Won't Be The Peak
Carpenter Technology (CRS) has transformed into a high-moat specialty alloys leader, supplying aerospace, defense, medical, and power sectors with unique, engineered metals. CRS reported record Q1 FY26 margins and income, with management projecting continued growth and margin expansion through at least 2027, driven by aerospace demand and long-term contracts. The Athens, Alabama expansion will add significant capacity by FY28 without eroding pricing power, while robust cash flow enables both reinvestment and shareholder returns via buybacks and dividends.
Carpenter Technology: A Pure Play On The Aerospace Superalloy Squeeze
Carpenter has transformed into a strategic supplier at the core of the aerospace industry, benefiting directly from higher engine production. Its pricing strength comes from the scarcity of certified nickel-based superalloy producers, which limits competition. The company continues to expand margins through selective production, efficiency, and disciplined cost control.
Carpenter Technology Q1 Earnings Beat Estimates, Revenues Rise Y/Y
CRS posts strong Q1 results with earnings and revenues topping estimates, driven by higher margins and solid Aerospace demand.
Carpenter Technology Corporation (CRS) Q1 2026 Earnings Call Transcript
Carpenter Technology Corporation (NYSE:CRS ) Q1 2026 Earnings Call October 23, 2025 10:00 AM EDT Company Participants John Huyette - VP of Corporate Development & Investor Relations Tony Thene - CEO & Chairman of the Board Timothy Lain - Senior VP & CFO Conference Call Participants Gautam Khanna - TD Cowen, Research Division Andre Madrid - BTIG, LLC, Research Division Joshua Sullivan - JonesTrading Institutional Services, LLC, Research Division Scott Deuschle - Deutsche Bank AG, Research Division Philip Gibbs - KeyBanc Capital Markets Inc., Research Division Bennett Moore - JPMorgan Chase & Co, Research Division Presentation Operator Thank you for standing by. At this time, I would like to welcome everyone to today's Carpenter Technology Q1 Fiscal Year '26 Earnings Presentation.
Carpenter (CRS) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
Although the revenue and EPS for Carpenter (CRS) give a sense of how its business performed in the quarter ended September 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Carpenter Technology (CRS) Q1 Earnings and Revenues Top Estimates
Carpenter Technology (CRS) came out with quarterly earnings of $2.43 per share, beating the Zacks Consensus Estimate of $2.13 per share. This compares to earnings of $1.73 per share a year ago.
Carpenter Technology to Report Q1 Earnings: What's in the Offing?
CRS is set to post Q1 fiscal 2026 results, with earnings projected to surge 23% on stronger aerospace, defense and medical demand.
